IP Library › Granted Patent US 7,547,771
Granted Patent B2
US 7,547,771 · App. 10/856,888 · Granted Jun 16, 2009

Polymorphic markers of prostate carcinoma tumor antigen -1(PCTA-1)

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,547,771
App. No.
10/856,888
Granted
Jun 16, 2009
Kind
B2
Abstract

The invention concerns the geNo.mic sequence and cDNA sequences of the PCTA-1 gene. The invention also concerns biallelic markers of the PCTA-1 gene and the association established between these markers and prostate cancer. The invention provides means to determine the predisposition of individuals to prostate cancer as well as means for the diagNo.sis of prostate cancer and for the progNo.sis/detection of an eventual treatment response to agents acting against prostate cancer.

Claims (45)

1. An isolated, purified or recombinant polynucleotide comprising SEQ ID NO: 12 or the complement thereof.

2. An isolated or purified human polynucleotide consisting of a contiguous span of SEQ ID NO: 12 or the complement thereof, wherein said contiguous span includes the biallelic marker at position 67092 of SEQ ID NO: 12 and said contiguous span is:

a) nucleotides 1-70715;

b) 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500 or 1000 contiguous nucleotides of SEQ ID NO: 12;

c) nucleotides 1-70715 attached to a label or solid support; or

d) 12, 15, 18, 20, 25, 30, 35, 40. 50, 60, 70, 80, 90, 100, 150, 200, 500 or 1000 contiguous nucleotides of SEQ ID NO: 12 attached to a label or solid support.

3. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of nucleotides 1-70715.

4. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of nucleotides 1-70715 attached to a label.

5. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of nucleotides 1-70715 attached to a solid support.

6. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 12 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

7. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 15 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

8. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 18 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

9. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 20 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

10. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 25 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

11. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 30 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

12. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 35 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

13. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 40 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

14. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 50 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

15. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 60 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

16. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 70 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

17. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 80 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

18. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 90 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

19. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 100 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

20. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 150 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

21. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 200 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

22. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 500 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

23. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span consists of 1000 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

24. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 12 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

25. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 15 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

26. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 18 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

27. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 20 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

28. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 25 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

29. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 30 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

30. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 35 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

31. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 40 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

32. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 50 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

33. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 60 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

34. The isolated or purified ha polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 70 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

35. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of SO contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

36. The isolated or purified ha polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 90 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

37. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 100 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

38. The isolated or purified human polynucleotide according to claim 2 ,wherein said contiguous span is attached to a label or solid support and consists of 150 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

39. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 200 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

40. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 500 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

41. The isolated or purified human polynucleotide according to claim 2 , wherein said contiguous span is attached to a label or solid support and consists of 1000 contiguous nucleotides of SEQ ID NO: 12 and includes the biallelic marker at position 67092 of SEQ ID NO: 12.

Assignments (2)
CHANGE OF NAME Recorded Aug 3, 2005
From: GENSET S.A.
To: SERONO GENETICS INSTITUTE S.A.
Reel/Frame 016348/0865 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2004
From: BLUMENFELD, MARTA; BOUGUELERET, LYDIE; CHUMAKOV, ILYA
To: GENSET S.A.
Reel/Frame 015084/0667 →